里桑基祖马布在克罗恩氏病中的多中心现实世界结果:RESOLVE IG-IBD研究
Franco Scaldaferri1,2, Federica Di Vincenzo1,2, Marina Aloi3
1IBD Unit - Centro di Malattie dell'Apparato Digerente (CeMAD), UOC Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
The American journal of gastroenterology
|February 18, 2026
概括
瑞桑基祖马布 (RZB) 在克罗恩氏病 (CD) 患者中显示出有效性,达到显著的临床和内镜缓解. 这项现实研究证实了RZB作为耐火CD的有价值的治疗选择.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病 (CD) 是一种慢性炎症状况,需要有效的长期治疗.
- 耐火性CD是一个重大挑战,需要新的治疗方法.
- 现实世界的数据对于了解不同患者群体的治疗有效性至关重要.
研究的目的:
- 评估Risankizumab (RZB) 在大量成年克罗恩病患者队列中的实际有效性和安全性.
- 评估多个时间点的临床和内镜缓解率,长达52周.
- 为了比较ustekinumab暴露与 ustekinumab未接触患者的结果,并根据先前的治疗失败来分析有效性.
主要方法:
- 一个多中心的,回顾性观察队列研究520名成人患者开始RZB.
- 同主终点包括第12周无类固醇临床缓解 (SFCR) 和第52周内缓解.
- 作为观察结果,分析了有效性,使用非响应者的归算进行了敏感性分析.
主要成果:
- 在第12周,60.8%的患者实现了SFCR. 到第52周,SFCR为65.6%,内镜缓解率达到37.5%.
- 之前未服用乌斯提金巴的患者表现明显好于暴露于乌斯提金巴的患者.
- 52周的疗效与之前治疗失败2次和≥3次的患者之间是可比的. 里桑基祖马布 (risankizumab) 的耐受性很好.
结论:
- 瑞桑基祖马布 (RZB) 在现实世界,耐火性CD人群中表现出快速和持续的临床,内镜和放射性改善.
- 对于耐火性CD来说,RZB是一种有价值的治疗选择,无论之前有2次或≥3次治疗失败,其效果在一年内都相当.
- RZB的安全概况是有利的,在这个队列中没有发现新的安全信号.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
607
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
607
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
574
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
574
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
542
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
542
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
489
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
489
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
817
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
817